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Abstract 
Objectives: Impulse Control Disorders (ICDs) LQ3DUNLQVRQ¶VGLVHDVH 3' have previously 
almost exclusively been considered to result from anti-parkinsonian medication. However, 
this biomedical perspective has failed to achieve a full understanding of the phenomenon and 
it is argued that a failure to consider psychological factors is a critical omission. Design: The 
present study examined the predictive relationship between ICDs in PD and a range of 
psychological measures, whilst controlling for a number of biomedical determinants. Main 
outcome measures: One hundred participants with idiopathic PD completed questionnaires 
that assessed demographic and clinical characteristics, psychological measures and the 
presence of ICDs (QUIP-RS). Results: Increased use of a µQHJDWLYH¶coping strategy, stronger 
illness identity, more emotional illness representations and stress were found to be significant 
predictors of ICDs, and different psychological predictors were associated with different 
ICDs. Medication was not found to predict ICDs in the presence of psychological factors, 
either when total treatment levels were considered or when agonist dose was considered 
alone. Conclusions: This study provides the first quantitative evidence of a predominant 
predictive relationship between psychological factors and ICDs in PD. The results suggest 
that psychological interventions may have a useful therapeutic role to play for ICDs in PD. 
 
Key words: impulsivity; biomedical determinants; psychological determinants; coping; illness 
perceptions   
2 
 
Introduction 
3DUNLQVRQ¶VGLVHDVH 3' LV DSURJUHVVLYHQHXURGHJHQHUDWLYHGLVRUGHUFDXVHG by the loss of 
dopamine containing neurons primarily within the substantia nigra pars compacta of the 
midbrain (Obeso et al., 2000; Moore, 2003). The disease is typically characterised and 
diagnosed by a syndrome of bradykinesia, tremor, and muscular rigidity (Stern, 1988; Gelb, 
Oliver & Gilman, 1999). Research has tended to focus on the motor symptoms associated 
with PD, and although a number of non-motor symptoms are now recognised to be part of the 
disease, non-motor symptoms have received comparatively less attention (Chaudhuri, Healy, 
& Schapira, 2006; Gallagher, Lees, & Schrag, 2010). The most common non-motor 
symptoms are argued to include depression, anxiety, psychosis, sleep problems and impulse 
control disorders (ICDs; Chaudhuri et al., 2006; Chaudhuri & Schapira, 2009). Impulse 
control disorders have received growing attention as a feature of PD in recent years and 
include pathological gambling, compulsive buying, hypersexuality and compulsive eating 
(Giladi, Weitzman, Schreiber, Shabtai, & Peretz, 2007; Voon & Fox, 2007; Weintraub, 
2008). Hobbyism (repeated ritualistic behaviours), punding (illogical ritualistic behaviours) 
and Dopamine Dysregulation Syndrome (personal escalation of medication doses) are also 
reported in the population (Ferrara & Stacy, 2008; Weintraub, 2008). 
 
Aside from the range of difficulties in basic living skills people with PD often experience on 
a daily basis (Bramley & Eatough, 2005), ICDs carry their own consequences, frequently 
destabilising family life and causing significant financial losses (Voon & Fox, 2007). This 
added stressor multiplies the complexity of living with PD and has been found to have a 
VLJQLILFDQWGHWULPHQWDOHIIHFWRQSHRSOH¶VTXDOLW\RIOLIH3KXHWDO$OWKRXJK,&'VDUH
commonly under reported (Vilas, Pont-Sunyer, & Tolosa, 2011), it is estimated that between 
10 and 14% of people with PD have ICDs (Giladi et al., 2007; Poletti et al., 2013; Weintraub, 
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Potenza, Siderowf, & Voon, 2010), compared to between 1 and 8% within the general 
populaWLRQ 'HOO¶2VVR $OWDPXUD $OOHQ Marazziti, & Hollander, 2006). Where explicit 
comparisons have been made between people with PD and matched controls, ICDs are 
DURXQG WZLFH DV FRPPRQ LQ 3DUNLQVRQ¶V SDWLHQWV WKDQ LQ FRQWUROV 5RGULJXH]-Violante, 
Gonzalez-Latapi, Cervantes-Arriaga, Camacho-Ordonez, & Weintraub, 2015), although the 
difference can be even greater (Perez-Lloret, Rey, Fabre, Ory, Spampinato, Brefel-Courbon, 
Montastruc, & Rascol, 2012). 
 
To date, research into ICDs in PD has largely investigated associated risk factors from a 
biomedical perspective, concentrating on the role of dopamine replacement therapies, 
consisting of L-dopa and dopamine agonists used to treat motor symptoms (e.g. Voon, 
Potenza, & Thomsen, 2007). For example, research suggests that there is an increased 
prevalence of ICDs in people taking dopamine agonists, compared with those on other forms 
of dopamine replacement therapy (Weintraub, 2008; Weintraub et al., 2010), and ICDs have 
been shown to occur after an increase of dopamine agonist dosage over the course of the 
disease and to decrease after a reduction of dopamine agonist dosage in some (though not all) 
cases (Dodd et al., 2005). Within this theoretical framework, it is widely hypothesised that 
dopamine replacement therapies interact with the systems in the brain that reinforce 
behaviour and that engagement in impulsive-compulsive behaviours occurs as a result of the 
increased activation of these systems (Voon & Fox, 2007). 
 
However, despite some support for dopamine agonist medication being linked to an increased 
prevalence of ICDs in PD (Lim, Evans, & Miyasaki, 2008), only a small percentage of those 
taking the medication are actually diagnosed with ICDs (Weintraub et al., 2006; 2010). The 
majority of patients do not develop ICDs even though they are often on very similar 
4 
 
dopamine replacement therapy treatment regimes to those who do (see for example 
Weintraub et al., 2010). Likewise, 7RXUHWWH¶V V\QGURPH where a functional increase in 
dopamine-mediated transmission is considered a central component of the disorder (Minzer, 
Lee, Hong, & Singer, 2004), has not been associated with ICDs. Impulse control disorders 
themselves are not limited to PD and have been described in other chronic conditions such as 
angina and arthritis (Pietrzak, Morasco, Blanco, Grant, & Petry, 2007), dementia (Mendez, 
Bronstein, & Christine, 2000) and multiple sclerosis (Ceschin, Giannunzio, Favaro, & 
Santonastaso, 2010), where there is no explicit dopamine involvement. Finally, a solely 
biomedical perspective cannot easily provide insight into why a patient develops one ICD 
rather than another. So, although the case for the relationship between dopamine (and 
dopamine agonists) and ICDs in PD has some support, the field is still far from achieving a 
full understanding of the factors that underlie ICDs in PD. 
 
The deficiencies in a solely biomedical perspective suggest that other important causative 
factors must be involved in the genesis of ICDs in PD. In relation to this, Lim et al. (2008) 
had a potentially critical insight when they speculated that how the patient copes with having 
a chronic illness may play a role in the development and maintenance of ICDs in PD. 
Qualitative work supports this: Hence, Delaney, Simpson and Leroi (2011) report that during 
interviews some PD patients with ICDs attribute the cause of their ICDs to the emotional 
impact of the disease and their way of coping with that impact. In these patients, ICDs reflect 
problem-focused coping strategies concerned with managing the problem (PD) that created 
stress in their lives, and emotion-focused strategies concerned with minimizing negative 
emotions associated with the stress through cognitive or emotional avoidance. A priori it 
seems plausible that a psychological perspective based on characteristics of the patient and 
the psychological consequences of living with a chronic, progressive illness might have much 
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to offer if one was seeking to understand the basis for the marked individual differences in 
the propensity for PD patients to develop ICDs in the presence of a common pharmaco-
therapeutic background. Indeed DSHUVRQ¶VSHUFHSWLRQRI WKHLU LOOQHVV LV WKRXJKW WRKDYHDQ
important role to play in the adjustment a patient makes to a chronic condition (Leventhal, 
Nerenz, & Steele, 1984). 
 
Given that the current biomedical approach to ICDs in PD has achieved an incomplete 
understanding of the phenomenon, whilst at the same time evidence suggests that 
psychological factors are likely to play an important in the genesis of ICDs in PD, there is an 
urgent need to more fully explore the relationship between psychological factors and ICDs in 
PD. Identifying the causal factors underlying ICDs in PD will have important implications for 
their treatment. Hence, in the current study, the relationships between coping, illness 
perceptions, anxiety, depression and stress in relation to ICDs were statistically examined 
using hierarchical block regression. In addition, studies to date have only looked at ICDs 
within the context of a clinical diagnosis and it is apparent that a significant proportion of PD 
patients do not report their difficulties with compulsive behaviour and therefore are not 
formally considered to have an ICD (e.g. Papay et al., 2011). Patients may also have 
compulsive behaviours that do not meet the full criteria for the relevant disorder in, for 
example, the DSM V (American Psychiatric Association, 2013). As a consequence, the 
current study was also concerned with exploring the predictors of subclinical ICDs in the PD 
population. 
 
Method 
Participants 
Participants (N = 100) were recruited from across the United Kingdom (UK) following 
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ethical approval from the National Health Service (NHS) research ethics committee and local 
NHS Trust. Potential participants were eligible to take part in the study if they had a 
diagnosis of idiopathic PD from a neurologist (with or without a clinical ICD diagnosis), 
were able to provide informed consent and were English speaking. In line with policies for 
practice and research in the UK, capacity to take part in the research was assessed on an 
individual basis (Dobson, 2008; Department for Constitutional Affairs, 2005). 
 
Participants were recruited through two possible routes, either from advertisements 
distributed by the charity 3DUNLQVRQ¶V 8. (PDUK) or by letter of invitation from their 
neurologist at a regional specialist hospital in the North of England. One hundred and 
nineteen potential participants contacted us to take part (104 responding to the advertisements 
and 15 responding to letters sent to participants from their neurologist). Of those who 
contacted us to take part, one was ineligible and was excluded at screening level as they had 
not yet received a diagnosis of PD confirmed by a neurologist. One further participant was 
excluded from the analysis as they failed to complete some of the questionnaires. No other 
participants were excluded, although 17 failed to return their responses after contacting us to 
take part. Where there were missing values (this was rare), instructions specific to scales were 
followed. Of the final 100 participants who completed the questionnaires (PDUK, n =  88; 
neurologist, n =  12), 34 chose to complete them by post and 66 chose to complete them 
online. All participants reported a diagnosis of idiopathic PD from a consultant neurologist 
within the NHS. 
 
Demographic and clinical predictor variables 
Demographic information included: age; gender; marital status; occupational status; and 
years of education. Self-reported clinical information included: number of years since PD 
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diagnosis using a three point scale (in the last year, up to two years and over three years); 
years since symptom onset on a three point scale (during the last year, between two and three 
years and since diagnosis); if participants had a diagnosis of ICD (yes/no); and if they had 
ever had surgery to fit a deep brain stimulator for motor control problems (yes/no). 
Participants were also asked to provide information about their current PD medication and if 
they had noticed any changes since starting their current medication UHJLPH 3DUNLQVRQ¶V
disease medications were transformed into a Levodopa equivalent daily dose (LEDD) for 
each participant, using the equivalencies recommended by Tomlinson et al. (2010). As in 
Weintraub et al. (2010), analysis was conducted separately for total LEDD and for agonist 
dose converted to an equivalent LEDD.  
 
Stage of illness and level of independence were assessed using self-report versions (see 
Schrag, Hovris, Morley, Quinn, & Jahanshahi, 2003; Schrag et al., 2007) of the Hoehn and 
Yahr (HY; Hoehn & Yahr, 1967) and Schwab and England (SE; Schwab & England, 1969) 
scales. The HY scale was developed to evaluate symptom severity for PD and its use is 
supported by the Movement Disorder Society Task Force for Rating Scales for Parkinson's 
disease (Goetz et al., 2004). The scale rates the stage of disease progression, ranging from 0 
(no signs of disease) to 5 (wheelchair/bed bound). The SE scale was developed to measure 
the functional abilities of people with PD and the amount of perceived support that a person 
feels they require in order to complete daily tasks. Scores range from 0% (no control over 
swallowing, bladder or bowels ± bed-ridden) to 100% (completely independent) with 10% 
increments. Although the scales are typically completed by clinicians, a self-administered 
version of each has been found to have strong correlations with clinician scores, with intra-
class correlation coefficients reaching r = .70 for the HY scale and r = .82 for the SE scale 
(Schrag et al., 2003). 
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Demographic and clinical information are presented in Table 1. The majority of participants 
were married and retired. Most participants reported being educated to degree level or had 
post-statutory educational qualifications. An equal number of male and female participants 
took part in the study, with time since diagnosis typically over three years, and with PD 
symptom onset also generally under three years. The disability scale scores were consistent 
with a population in the earlier stages of the condition, with a reasonable level of 
independence. A range of medications for PD were reported. The majority of participants 
(70.0%) were taking Levodopa, although a number (70.0%) were taking dopamine agonists 
(most prevalent: ropinirole [39.0%], pramipexole [27.0%] and rotigotine [4.0%]). A 
proportion (39%) were taking an inhibitor, either of peripheral decarboxylase activity (3%; 
carbidopa), monoamine oxidase (MAO)-B activity (32.0%; most prevalent: rasagiline 
[25.0%] and selegiline [7.0%]) or catechol-O-methyl transferase activity (COMT; 6%; most 
prevalent entacapone [5.0%]). Most participants felt that they had noticed changes in their 
condition since onset or had experienced changes in their medication regime. Three 
participants reported having previously had deep brain stimulation (DBS) surgery for their 
condition. Eleven (11.0%) participants reported a current clinical ICD diagnosis. 
 
Psychological predictor variables 
Abbreviated Coping Orientations to Problems Experienced scale (Brief COPE). The Brief 
COPE (Carver, 1997) is an abbreviated version of the original COPE inventory (Carver, 
Scheier, & Weintraub, 1989), consisting of 28 statements divided into 14 subscales: active 
coping; planning; positive reframing; acceptance; humour; religion; use of emotional support; 
instrumental support; self-distraction; denial; venting; substance use; behavioural 
disengagement; and self-blame. The subscales have a high level of consistency and reliability 
UDQJLQJIURPĮ IRUWKHYHQWLQJVXEVFDOHWRĮ IRUVXEVWDQce misuse (Carver, 1997). 
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The Brief COPE has been used in studies investigating PD and found to measure coping 
within acceptable limits (Dobkin et al., 2011; Simpson, Lekwuwa, & Crawford, 2013). 
 
Depression, Anxiety and Stress Scale (DASS). The DASS (Lovibond & Lovibond, 1995) is 
comprised of three self-report scales to measure current levels of depression, anxiety and 
stress. As the DASS subscales can be used independently, only the stress scale was used in 
the present study. The scale consists of 14 statements which are rated using a four-point 
/LNHUWVFDOHIURP³'LGQRWDSSO\WRPHDWDOO´WR³$SSOLHGWRPHYHU\PXFKRUPRVWRI
WKHWLPH´EDVHGRQH[SHULHQFHVRYHUWKHSDVWZHHN7KHVWUHVVVXEVFDOHVFRUHLVFDOFXODWHGE\
summing the items together with a maximum score of 42. Scores below 14 are considered to 
be levels that most people would experience. The stress subscale has been found to have high 
LQWHUQDOFRQVLVWHQF\Į &UDZIRUG	+HQU\DQGKDVEHHQXVHGZLWKSHRSOHZLWK
PD in previous research (Simpson, Haines, Lekwuwa, Wardle, & Crawford, 2006). Although 
the depression and anxiety scales on the DASS have been used in PD research, a number of 
the items have been argued to be confounded by physical symptoms of PD (Marinus, 
Leentjens, Visser, Stiggelbout, & van Hilten, 2002). Therefore the Hospital Anxiety and 
Depression Scale (Zigmond & Snaith, 1983) was considered more appropriate to measure 
anxiety and depression in this population. 
 
Hospital Anxiety and Depression Scale (HADS). The HADS (Snaith, 2003; Zigmond & 
Snaith, 1983) is 14-item self-report measure comprised of two subscales for current levels of 
anxiety and depression, scored on four-point Likert scales from 0 to 3, with higher scores 
representing greater levels of anxiety or depression. Each scale has a maximum score of 21, 
with scores between eight and ten indicating raised levels of anxiety or depression and scores 
DERYH  LQGLFDWLQJ µSUREDEOH FDVHQHVV¶ IRU DQ[LHW\ RU GHSUHVVLRQ 7KH DQ[LHW\ DQG
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depression scales have been found to demonstrate high internal consistency in 15 reviewed 
VWXGLHV &URQEDFK DOSKDV IURP Į    WR Į    IRU DQ[LHW\ DQG Į    IRU GHSUHVVLRQ
(Bjelland, Dahl, Haug, & Neckelmann, 2002). Similar results have been found for test-retest 
reliability in a population with PD (Marinus et al., 2002). 
 
Life History of Impulsive Behaviour questionnaire (LHIB-Q20). The LHIB-Q20 (Coccaro & 
Schmidt-Kaplan, 2012) is a self-report version of the Life History of Impulsive Behaviours 
interview (Schmidt, Fallon, & Coccaro, 2004). The scale consists of 20 statements relating to 
adult life rated on a six-SRLQW/LNHUWVFDOHIURP³QHYHU´WR³KDSSHQHGWRRPDQ\WLPHVWR
UHPHPEHU´ 7KHUH DUH FXUUHQWO\ QR QRUPDWLYH GDWD IRU WKH VFDOH KRZHYHU D KLJKHU VFRUe 
indicates a more impulsive life history. High scores on the self-report measure have been 
found to be consistent with diagnoses of ICDs made by clinicians using diagnostic criteria 
(Coccaro & Schmidt-Kaplan, 2012). The authors report high internal reliability for the LHIB-
4Į 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Illness Perceptions Questionnaire ± Revised (IPQ-R). The IPQ-R (Moss-Morris et al., 2002) 
is used to DVVHVV LQGLYLGXDOV¶ EHOLHIV DQG understandings about their illnesses. Validity and 
reliability have been confirmed across a range of clinical populations (see Llewellyn, 
McGurk, & Weinman, 2007). The IPQ-R includes subscales for: illness identity; cause of 
illness; timeline (chronic and cyclical); consequences; control (personal and treatment); 
coherence and emotional representations. With the exception of illness identity, all items are 
scored on a five-SRLQW/LNHUWVFDOHIURP³VWURQJO\GLVDJUHH´WR³VWURQJO\DJUHH´7KH
Identity subscale consists of illness symptoms, awarded a score of one if the symptom is 
present and related to the illness or zero if not. Higher scores on each subscale represent 
stronger beliefs for the domain. Good internal consistency for each of the subscales are 
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UHSRUWHG UDQJLQJ IURPĮ   IRU WKHF\FOLFDO WLPHOLQH WRĮ   IRU the chronic timeline 
(Moss-Morris et al., 2002). The authors state that adaptations should be made to the Identity 
and Cause subscales to describe illness specific symptoms and causes. In the present report, 
the Identity and Cause subscales were modified, based on and extending the changes made to 
the subscales in a previous study using a PD population, where 13 items were added to the 
Cause subscale and 18 were added to the Identity subscale (see Simpson et al., 2013a; 
Figures S1 and S2 in the supplemental online material). 
 
Outcome variable 
Questionnaire for Impulsive-compXOVLYH GLVRUGHUV LQ 3DUNLQVRQ¶V disease ± Rating Scale 
(QUIP-RS). The QUIP-RS (Weintraub et al., 2012) is a screening tool designed to measure 
the severity of ICD symptoms and assist with ICD diagnosis. Four subscales for ICDs 
(gambling, sexual compulsions, compulsive buying and compulsive eating) have possible 
scores between 0 and 16 and suggested cut-offs (scores validated as indicative of ICDs via 
clinical interview) as folloZVJDPEOLQJ  FRPSXOVLYHEX\LQJ  VH[XDO FRPSXOVLRQV
 FRPSXOVLYH HDWLQJ  DQG FRPELQHG ,&'V  7KH 48,3-RS also includes 
measures for hobbyism (involvement in organised activities like writing or computer use) and 
punding (repeating activities like cleaning). The two were combined into one subscale 
(hobbyism-punding; range = 0-32; cut-RIIGXHWRWKH significant overlap reported by the 
authors (Weintraub et al., 2012). Good inter-UDWHUĮ DQGUHWHVWĮ UHOLDELOLWLHVare 
reported for the questionnaire (Weintraub et al., 2012). Within the current study, the four ICD 
subscales and hobbyism-punding subscale were used as outcome variables in order to 
understand the relationship between the predictor variables and each type of ICD. The 
combined ICD score was used to establish the overall state impulsive characteristics of the 
sample and determine the number of participants reporting ICDs above the clinical cut-off. 
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Procedure 
Data collection. Participants initially contacted the research team in response to advertise-
ments distributed by PDUK or by letter of invitation from their neurologist. Following initial 
contact, they were screened for eligibility over the telephone by a researcher (JKG) and those 
with a diagnosis of idiopathic PD were provided with the option to complete questionnaires 
online or by post. Those choosing to complete the questionnaires by post were sent the 
questionnaire pack, consent form and pre-paid envelope. Those choosing to complete the 
questionnaires online received an email with a link to the questionnaires and consent form 
(hosted by SurveyGizmo). Participants were informed that the questionnaire pack would take 
about 45 minutes to complete, that it could be completed in sections over a maximum of one 
week and that they could withdraw from the study at any time without affecting their medical 
care. No participants reported difficulties completing the questionnaires and all 
questionnaires were completed within the week time frame. 
 
Statistical Analysis 
Statistical analyses were carried out using IBM SPSS Statistics (Version 21 for Macintosh).  
Comparisons between participants with higher and lower scores on the QUIP-RS were 
carried out using independent samples t-tests and hierarchical block regression analyses were 
conducted to investigate the relationship between predictor variables and the ICD outcome 
measures. Although for regression analysis, only dependent variables need to be normally 
distributed (Field, 2009), the QUIP-RS ICD subscale scores were not normally distributed (Z 
skewness > 1.96), therefore transformation was required (Tabachnick & Fidell, 2007). 
Optimal transformations were carried out for the dependent YDULDEOHV XVLQJ WKH µ%R[-&R[¶
procedure, which maximises the normality achievable via transformation of the data 
(Osborne, 2010). 6SHDUPDQ¶V FRUUHODWLRQV ZHUH XQGertaken where variables did not meet 
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assumptions of normal distribution to investigate the relationship between all demographic, 
clinical, psychological, coping and illness perceptions predictor variables and the ICD 
outcome variables (see Tables 2 and 3 for correlation coefficients). Only predictor variables 
significantly correlated with the ICD outcome variables at p < .01 were entered into the 
separate regression models due to the high number of correlations between variables (Edgar 
& Skinner, 2003; Simpson et al., 2013a; Simpson, Lekwuwa, & Crawford, 2014). Separate 
regression analyses were completed for each ICD (gambling, sexual compulsions, 
compulsive buying, compulsive eating and hobbyism-punding behaviours). Given the low 
percentage of people with PD experiencing two or more ICDs (3.9%; Weintraub et al., 2010), 
the relationship with the combined ICD score was not examined. Where predictor variables 
correlated at the required level with the outcome variables, blocks were conceptualised as 
follows: 
Block 1:  Demographic variables (gender, age, years of education, relationship status, 
employment status) 
Block 2:  Clinical variables (stage of illness, level of independence, years since diagnosis, 
years since onset, LEDD total, LEDD agonist, DBS, changes due to medication) 
Block 3:  Psychological variables (coping, trait impulsivity) 
Block 4:  Wellbeing (anxiety, depression, stress) 
Block 5:  Illness beliefs (IPQ-R) 
 
Prior to interpretation of the regression analyses, variables were checked for assumptions 
required for multiple regression analysis (i.e. multicollinearity, collinearity, homoscedasticity 
and independent errors; see Tabachnick & Fidell, 2007). Correlations between predictors did 
not indicate high levels of multicollinearity in the sample. Where there was evidence of 
correlation between predictor variables, moderation analysis was carried out to further 
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investigate the interaction, centring the variables where necessary. Residual scatter plots were 
drawn and did not indicate any violations for normality. Additionally, linearity and 
homoscedasticity assumptions were met. No evidence of auto-correlation using the Durbin-
Watson statistic (Durbin & Watson, 1971) in any of the models reported above was observed. 
Casewise diagnostics did not indicate any significantly influential cases, within what would 
be expected for general populations (Field, 2009). 
 
Results 
Participant characteristics 
Means and standard deviations for psychological and ICD variables are presented in Table S1 
in the supplemental online material. Scores on HADS revealed 39.0% of the sample to have 
raised levels of anxiety (with 19.0% iQ WKH µSUREDEOH FDVHQHVV¶ UDQJH DQG 32.0% of the 
sample to have raised levels of depression (with 7.0LQWKHµSUREDEOHFDVHQHVV¶UDQJH). On 
the DASS stress subscale, three participants (3.0%) were ZLWKLQ WKH µPLOG¶ UDQJH ZLWK DOO
UHPDLQLQJ SDUWLFLSDQWV LQ WKH µQRUPDO¶ UDQJH 9DULDWLRQ ZDV IRXQG in the extent to which 
various coping strategies were endorsed, the most frequently used strategies being 
acceptance, active coping, planning, and emotional and instrumental support. Responses to 
questions concerning illness beliefs showed stronger beliefs about health and psychological 
attributions for the cause of PD. Personal control of PD appeared to be more important than 
treatment control and participants held strong beliefs about the consequences of their illness. 
More emotional representations about the illness were reported alongside beliefs that the 
illness would last a long time. 
 
Despite the slightly lower than expected presentation of confirmed clinical ICD diagnoses 
(11.0%), responses for the combined ICD subscales (total QUIP-RS scores) showed a high 
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SURSRUWLRQRISHRSOHLQWKHµFOLQLFDO¶UDQJHFRPELQHGVFRUHn = 59, 59.0%). A number 
of impulsive behaviours in the clinical range were described using individual ICD scales 
within the sample. There were reports of hobbyism-punding (n = 45, 45%), compulsive 
eating (n = 29, 29.0%), sexual compulsions (n = 16, 16.0%) and compulsive buying (n = 11, 
11.0%), indicating the presence of a range of compulsive behaviours in the sample. Gambling 
(n = 3, 3.0%) was the least reported ICD. 
 
Considering those participants with total QUIP-RS scores in the clinical range versus those 
with scores below the clinical range, participants in the higher combined ICD group reported 
significantly greater scores on measures of emotional distress (anxiety, depression and stress) 
and increased use of more problematic coping strategies (self-distraction, substance use and 
self-blame; Table 2). They also reported more dominant emotional illness representations, 
increased perceived number of symptoms related to PD and beliefs that their illness was 
related to their environment. There were no significant differences between the total LEDD in 
those with higher and lower total QUIP-RS scores (mean ± 1 SD: 804.85 mg ± 501.87 vs 
629.16 ± 480.17 mg respectively; t[98] = 1.752, p > .05, d = 0.354), or between the agonist 
equivalent LEDD in those with higher and lower total QUIP-RS scores (618.81 mg ± 593.15 
vs 522.36 mg ± 512.35 respectively; t[98] = .845, p > .05, d = .171). Furthermore, the 
frequency of ICDs was not significantly different in those taking dopamine agonists and 
those not taking dopamine agonists Ȥ2 = .096, p > .05, odds ratio = 1.147). When different 
combinations of drug treatment (Levodopa only; Levodopa + agonist; Levodopa + 
inhibitor(s); Levodopa + agonist + inhibitor(s); agonist + inhibitor; agonist only and inhibitor 
only) were compared to each other and participants receiving no medication using one-way 
ANOVA, there was a significant main effect of treatment (F(7,92) = 2.428, p < .05, Ș2 = 
.156).  Although there was a trend for participants in the no medication group to have the 
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lowest QUIP-RS scores (mean ± 1 SD, 4.00 ± 3.23) and those in the Levodopa only group to 
have the highest (mean ± 1 SD, 16.20 ± 7.61), none of the post hoc comparisons (using 
7XNH\¶V+RQHVW6LJQLILFDQW'LIIHUHQFHWHVWZHUHVLJQLILFDQW 
 
Multiple Regression Analyses  
Correlations were carried out between each of the predictor variables and outcomes as 
described above (Tables 3 and 4). Multiple regression analyses were then carried out for the 
individual ICD subscales to further understand the relationships with the demographic, 
clinical and psychological predictors. Table 5 provides beta weights and standard error scores 
for each of the models below.  
 
Hobbyism-punding. No clinical variables significantly correlated at the specified level with 
the hobbyism-punding outcome variable and these were therefore excluded from the model. 
Gender (Table 3), substance use and self-distraction coping, and illness cognitions for cause 
(Table 4) were correlated at the specified level with hobbyism-punding, hence gender was 
entered in block 1 and accounted for 6.4% of variance (R2 = .064, p = .011). Substance use 
and self-distraction coping were entered into block 2, accounting for 12.3% additional 
variance (R2 = .186, R2 change = .123, p = .001). Illness cognitions for cause (chance and 
psychological attributions) were entered in block 3 and accounted for 4.1% additional 
variance (R2 = .228, R2 change = .041, p = .086). Regression coefficients for predictors in 
the full model VKRZHGPDOHJHQGHUȕ , t = 2.385, p = .019), increased substance use 
FRSLQJ ȕ   , t = 2.918, p = .004) and increased self-GLVWUDFWLRQ FRSLQJ ȕ   , t = 
2.219, p = .029) to significantly predict hobbyism-punding scores. The total variance 
explained by this model was 18.6% (F(3,96) = 7.319, p < .001; Table 5). 
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Compulsive eating. No significant relationships at the specified level were found for clinical 
or demographic variables with the compulsive eating outcome variable (Table 3), however 
substance use coping and stress were correlated to the required level (Table 4). Substance use 
coping was therefore entered as block 1, accounting for 8.1% variance (R2 = .081, p = .004). 
Stress was then entered in block 2 and accounted for 5.2 % additional variance (R2 = .132, R2 
change = .052, p = .018). Regression coefficients for predictors in the full model revealed 
LQFUHDVHGVXEVWDQFHXVHFRSLQJȕ W  p  DQGLQFUHDVHGOHYHORIVWUHVVȕ
= .237, t = 2.411, p = .018) to be significant predictors of eating compulsions with the model 
explaining 13.2% of the total variance (F(2,97) = 7.407, p = .001; Table 5). 
 
Sexual compulsions. Significant relationships at the specified level were found for total 
LEDD, level of independence and gender with the sexual compulsions outcome variable 
(Table 3), and these were entered into block 1, explaining 21.5% of variance (R2 = .215, p < 
.001). Only gender was a significant independent predictor (R2 = .060, p < .05). Self-
distraction coping was entered into block 2 and accounted for 6.5% additional variance (R2 = 
.280, R2 change = .065, p = .004). Illness cognitions (identity, emotional representations and 
consequences) were entered in block 3, accounting for 11.14% additional variance (R2 = 
.392, R2 change = .111, p = .001). Regression coefficients for predictors in the full model 
VKRZHGPDOHJHQGHUȕ   W S  ), stronger LOOQHVV LGHQWLW\ ȕ   W 
2.654, p = .009) and more emotional iOOQHVVUHSUHVHQWDWLRQVȕ W , p = .001) to 
be significant predictors of sexual compulsions in the sample, whilst level of independence, 
total LEDD, self-distraction coping and consequences were no longer significant predictors. 
The total variance explained by the model was 39.2% (F(7,92) = 8.460, p < .001; Table 5). 
 
Given the interest in the literature concerning the relationship between ICDs in PD and 
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medication status (see Introduction), and the significant relationship at the specified level for 
total LEDD with the sexual compulsions outcome variable, the possibility was explored that 
total LEDD may moderate the effects of certain predictors on sexual compulsions. Levodopa 
Equivalent Daily Dose correlated at a low level (< .2) with most psychological predictors. 
However, correlations were significant with illness identity (r = .276, p < .01) and 
consequences (r = .233, p < .05), so interaction terms for these with LEDD were entered as 
additional predictors in the final model. Although these interaction terms accounted for 1.2% 
of additional variance, this was not significant (R2 = .404, R2 change = .012, p = .384), and 
neither emerged as significant independent predictors. 
 
Compulsive buying. No significant relationships were found at the specified level for clinical 
or demographic variables with the compulsive buying outcome variable (Table 3), although 
substance use coping and stress were correlated to the required level (Table 4). Substance use 
coping was therefore entered in block 1 and accounted for 10.3% variance (R2 = .103, p = 
.001). Stress was then entered in block 2 and accounted for 3.2 % additional variance (R2 = 
.135, R2 change = .032, p = .061). Regression coefficients for predictors in the full model 
revealed increased substance use coping was the sole VLJQLILFDQW SUHGLFWRU ȕ    W  
3.353, p = .001) of buying compulsions. The total variance explained by the model was 
10.3% (F(1,98) = 11.241, p = .001; Table 5). 
 
Gambling. As discussed earlier, only a small number of participants (n = 3) reported QUIP-
RS scores in the clinical range for the gambling subscale and consequently no significant 
relationships at the specified level were found with any of the predictor variables. 
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Discussion 
Impulse Control Disorders in PD have largely been considered from a biomedical perspective 
up to now, with PD medication seen as the primary causative factor. However, evidence 
suggests that psychological factors may also play an important role in the genesis of these 
disorders ± a contention which receives considerable support from the current study. Illness 
beliefs in the form of a stronger illness identity (identification with the illness label), more 
psychological distress (increased emotional representations and stress) and µnegative¶ coping 
styles (more substance abuse coping and self-distraction coping) were found to explain a 
significant amount of variance in ICDs. The overall findings of the current study provide the 
first quantitative evidence for relationships between coping, illness beliefs, psychological 
distress and ICDs in people with PD. Previous research has hinted at the importance of 
psychological factors in ICDs in PD. For example, Voon and colleagues (2007; 2011) suggest 
that certain psychological factors such as strong novelty seeking traits and lack of concern for 
the future are associated with ICDs in PD. However, the current findings are the first 
demonstration that psychological factors can be the predominant predictors of ICDs in PD.  
 
Although previous research has suggested ICDs to be present in 13.0-14.0% of people with 
PD when assessed by clinical interview (Weintraub et al., 2010; Papay et al., 2011), the 
current sample reported a significantly higher level, reaching 59.0% on a self-report measure, 
the QUIP-RS, when using clinically validated cut offs for ICDs. Similarly high (>30%) 
prevalence rates have been reported in other studies using the QUIP-RS (Papay et al., 2011; 
Lim et al., 2011; Goerlich-Dobre et al., 2014). Given that the diagnosed prevalence of ICDs 
in the current study was close to that reported elsewhere (11.1%), the greater level of self-
reported ICDs supports the theory that ICDs are under reported and often may not always be 
recognised by clinicians (Vilas et al., 2011; Voon & Fox, 2007). 
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Perhaps the most significant point of departure of the current results from previous findings is 
in relation to dopamine replacement therapies as predictors of ICDs in PD. Previous reports 
suggest that there is an increased prevalence of ICDs in people taking dopamine agonists, 
compared with those on other forms of dopamine replacement therapy (e.g. Weintraub, 2008; 
Weintraub et al., 2010; Hurt et al., 2014), and ICDs have been shown to occur after an 
increase of dopamine agonist dosage over the course of the disease and to decrease after a 
reduction of dopamine agonist dosage in some cases (Dodd et al., 2005). However, in the 
present study, dopamine replacement therapies (total LEDD and dopamine agonist dose 
converted to a LEDD) were not associated with ICDs. Participants with higher total QUIP-RS 
scores did not have significantly different total LEDD levels or dopamine agonist dose levels 
to those with lower scores, nor were they more likely to be taking agonist medication. While 
LEDD was significantly correlated at the specified level with sexual compulsions, LEDD was 
not a significant independent predictor (when entered alongside level of independence and 
gender). Although there are many previous reports which link ICDs in PD to dopamine 
replacement therapies (especially dopamine agonists), not all previous studies concur. In PD 
patients prescribed several forms of dopamine replacement therapy in conjunction, overall 
LEDD has sometimes not been found to predict ICD development (Voon et al., 2007; Isaias 
et al., 2008). Furthermore, although some studies have reported that dopamine agonists create 
an increased risk of developing ICDs others have not demonstrated this relationship (Lee et 
al., 2010; Hurt et al., 2014). Delaney, Leroi, Simpson and Overton (2012) hypothesise that 
medication may be D µVXVFHSWLELOLW\ PXOWLSOLHU¶ ZKLFK RSHUDWHV LQ FRQMXQFWLRQ ZLWK
psychosocial factors to determine whether the psychological distress (depression, anxiety and 
stress) caused by living with a chronic illness exceeds some threshold and leads to the 
development ICDs. The results of the present study suggest that psychological factors alone 
may be sufficient to exceed that threshold. 
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The present results also suggest that particular constellations of psychological factors may 
determine which ICDs will emerge. Where relevant, demographic and clinical variables were 
entered into the regressions early on and accounted for a proportion of the variance (generally 
R2 < .2) for hobbyism-punding and sexual compulsions. However, adding in psychological 
variables increased the amount of variance accounted for by the model in both cases. 
Although self-distraction, substance use, stress and illness identity had shared influences on 
hobbyism-punding and sexual compulsions, the latter was also associated with illness 
consequences and emotional representations. Substance use alone was associated with 
compulsive buying and when twinned with stress, substance abuse was associated with 
compulsive eating. 
 
Clinical implications: At present, the primary clinical response to ICDs in PD is to reduce the 
dopamine agonist medication (Macphee & Carson, 2013). Motor symptoms are sometimes 
significantly worsened when dopamine agonist medication is reduced, even though L-dopa 
doses may be increased to compensate (Lim et al., 2008). Therefore, people who develop 
ICDs in PD may be reluctant to discontinue dopamine agonist use, due to the motor symptom 
benefits. Furthermore, manipulating dopamine agonist therapy is not always successful in 
treating ICDs (Dodd et al., 2005). The finding that psychological factors have a significant 
predictive role in ICDs in PD suggests that there may be a role for other therapeutic 
approaches, such as psychological interventions, to be used alongside pharmacotherapies, and 
initial indications are that these approaches ± such as Cognitive Behaviour Therapy (CBT) 
(Jiménez-Murcia et al., 2012; Okai et al., 2013) and support groups (Kurlan, 2004; 
Mamikonyan et al., 2008) - can be effective. However, our understanding of psychological 
involvement in ICDs in PD is still in its infancy, although the present study suggests that the 
current approach to using CBT in ICDs in PD (where µVHFRQG ZDYH¶ WKHUDSLHV EDVHG RQ
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challenging dysfunctional thoughts have been used ± therapies that in their manual-based 
form have a major focus on symptom reduction, e.g. Cukor, 2007) may not be appropriate. 
Our study suggests that interventions need to take a different tack and explore the purpose 
behind the expressed ICDs (e.g. copiQJ« 7KHVH EHKDYLRXUV DUH FOHDUO\ IDU IURP LGHDO
however they fulfil an adaptive role to play for the people involved. A number of third wave 
cognitive behavioural therapies may be more appropriate for managing the psychological 
distress and problematic coping patterns associated with PD. Mindfulness based interventions 
and Acceptance and Commitment Therapy (ACT) have begun to receive attention within 
chronic illness research (e.g. Bohlmeijer, Prenger, Taal, & Cuijpers, 2010; Dahl, Wilson, & 
Nilsson, 2004; Fitzpatrick, Simpson, & Smith, 2010). Interventions have focused on 
adjustment to illnesses such as diabetes, drug refractory epilepsy and chronic pain (Gregg, 
Callaghan, Hayes, & Glenn-Lawson, 2007; Lundgren, Dahl, Melin, & Kies, 2006; Wetherell 
et al., 2011). The focus of intervention involves working with adjustment issues related to 
acceptance of the chronic illness and focusing on living in the present moment rather than 
focusing on the illness symptoms. Results have shown significant reductions in psychological 
distress as well as improvements in more adaptive coping strategies. There remains a demand 
for further research within PD to adapt appropriate therapies to help people develop more 
helpful beliefs about their illness and develop more positive coping strategies. Given the 
demonstrated importance of psychological factors in ICDs in PD, psychological therapies in 
the future could form the basis for a significant improvement in the management of these 
problematic symptoms. Indeed, further use of support groups may allow the opportunity to 
for patients to discuss and explore the personal story behind their behaviour without a priori 
medicalisation, and at the same time reduce psycho-emotional problems arising from stigma 
(Simpson, McMillan, & Reeve, 2013; Simpson, & Thomas, 2015) that may be themselves be 
disabling via depression (Simpson, et al., 2013b) and hence the subsequent impact on quality 
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of life (Simpson et al., 2014). 
 
Limitations: While the current report represents a useful addition to understanding the 
determinants of ICDs in PD, there are limitations worth noting. Firstly, on the whole the 
correlation coefficients and R2 values in the current study, although often significant, were in 
many cases reasonably small (r was often between .2 and .3, and R2 often < .2). This 
suggests that there are ultimately a large number of factors associated with ICDs in PD, 
alongside those reported here. Previous work by other authors has identified predictive 
relationships between personality factors, gambling problems in first-degree relatives and 
current smoking status, and ICDs in PD (Weintraub et al., 2010; Voon et al., 2011). We 
hypothesise that this list can be augmented by other factors, including additional 
psychological factors such as social support. In short, the relatively small correlation 
coefficients and R2 values point to the interesting conclusion that ICDs in PD have a multi-
factorial cause. 
 
Secondly, in the multiple regression analyses, we pre-screened all predictors for significant 
correlations with the DV and entered only those with significant (< .01) univariate p values. 
Although this data driven method of subset selection can be defended for an exploratory 
study like the present one, other methods are also possible, although their requirement for a 
greater a priori understanding of the relationship between predictors and the outcome 
measure, and/or a larger sample size, confine these approaches to the future. Hence, 
Steyerberg, Eijkemans, Harrell, and Habbema (2001) conclude that predictors are best 
VHOHFWHGRQWKHEDVLVRIµH[WHUQDOLQIRUPDWLRQ¶ZKLFKLVODFNLQJIRUSV\FKRORJLFDOSUHGLFWRUV
of ICDs in PD. Approaches like stepwise regression would impose the least bias, however 
with our large number of predictors and 100 participants, we would greatly exceed the 
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maximum number of predictors to be statistically robust (Harris, 1985 - the number of 
participants should exceed the number of predictors by at least 50; Green, 1991 - N > 50 + 
8m, where m is the number of predictors). 
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Table 1 
Participant demographic and clinical information (N =  100) 
Variable M (SD) or n (%) 
Age 64.39 (9.73) 
Gender (male) 50 (50%) 
Years of education 14.22 (2.29) 
Marital status  
 Single 1 (1%) 
 Married 79 (79%) 
 Living with partner 6 (6%) 
 Divorced/separated 8 (8%) 
 Widowed 6 (6%) 
Employment status  
 Employed (Full-time/Part-time) 12/11 (12%/11%) 
 Self-employed 3 (3%) 
 Student 1 (1%) 
 Retired 69 (69%) 
 Unemployed 4 (4%) 
DBS surgery for PD 3 (3%) 
Confirmed clinical ICD diagnosis 11 (11%) 
Years since PD diagnosis  
 < 1 year 3 (3%) 
 1-3 years 23 (23%) 
 > 3 years 74 (74%) 
Years since symptom onset  
 < 1 year 12 (12%) 
 1-3 years 50 (50%) 
 > 3 years 38 (38%) 
Hohen and Yahr  1.78 (1.32) 
Schwab and England  76.40 (17.34) 
Levodopa equivalent daily dose [LEDD] (mg) 732.83 (498.26) 
Dopamine agonist daily dose [as LEDD] (mg) 579.26 (560.76) 
Changes due to medication 86 (86%) 
Note. DBS = Deep brain stimulation surgery. 
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Table 2 
Between group analysis for higher (n =  59) and lower (n =  41) combined Impulse Control Disorder responses 
 
Variable 
High 
M (SD) 
Low 
M (SD) t      p 
 
    d 
COPE ± Self-distraction 4.78 (1.63) 3.73 (1.64) 3.15** .002 .636 
COPE ± Substance use 2.73 (1.22) 2.12 (0.46) 3.05** .003 .616 
COPE ± Self-blame 3.42 (1.74) 2.59 (1.07) 2.74** .007 .554 
HADS ± Anxiety 7.51 (4.10) 5.66 (3.37) 2.38* .019 .481 
HADS ± Depression 6.64 (3.53) 4.49 (2.84) 3.25** .002 .657 
DASS ± Stress 11.42 (7.61) 7.27 (5.29) 3.02** .003 .610 
IPQ-R ± Identity 16.66 (6.23) 12.83 (7.22) 2.83** .006 .572 
IPQ-R ± Consequences 24.21 (3.79) 22.34 (5.54) 2.01* .047 .406 
IPQ-R ± Emotional representations 19.85 (4.43) 17.61 (4.92) 2.37* .020 .479 
IPQ-R ± Environmental attributions 11.14 (3.36) 9.64 (3.11) 2.25* .026 .455 
  Note. COPE = Abbreviated coping orientations to problems experienced scale. HADS = Hospital anxiety and 
depression scale. DASS = Depression, anxiety and stress scale. IPQ-R = Illness perceptions questionnaire 
revised. d  &RKHQ¶Vd. *p < .05; **p < .01 
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Table 3 
Correlation coefficients for demographic, clinical predictors and Impulse Control Disorder variables (N =  100) 
Variable Gamb. Sex Buying Eating HBY-P 
Age 0.067 -0.017 -0.102 0.014 0.088 
Gender 0.027 .405*** -0.007 0.037 .286** 
Years of education 0.049 -0.061 -0.07 -0.128 -0.131 
Relationship status a 0.012 0.169 -0.134 -0.111 0.043 
Employment status a -0.149 -0.014 0.077 -0.107 -0.051 
DBS for PD a 0.065 0.107 0.134 -0.059 0.001 
Years since diagnosis b -0.094 -0.063 -0.037 -0.052 -0.126 
 0.035 -0.036 0.011 0.028 -0.049 
 0.003 0.059 0.004 -0.007 0.096 
Years since symptom onset b -0.131 -0.042 -0.144 -0.018 -0.165 
 0.045 -0.044 .211* 0.087 0.066 
 0.042 0.074 -0.121 -0.078 0.043 
Hoehn and Yahr 0.033 -0.064 -0.011 -0.043 -0.003 
Schwab and England -0.134 -.269** 0.086 0.023 -0.137 
Levodopa equivalent daily dose 0.089 .264** 0.072 0.032 0.113 
Dopamine agonist daily dose 0.013 0.161 -0.063 0.097 0.091 
Medication changes 0.034 0.167 0.058 0.123 0.047 
Note. DBS = deep brain stimulation surgery. a = dummy coded (0 = not in a relationship/not working/not DBS, 
1 = in a relationship/working/DBS). b = dummy coded (<1yr, 1-3yrs or >3yrs). Gamb. = Gambling. HBY-P = 
Hobbyism-punding. *p < .05; **p < .0; ***p < .001 
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Table 4 
Correlation coefficients for psychosocial predictor and Impulse Control Disorder variables (N =  100) 
Predictor variable Gamb. Sex Buying Eating HBY-P 
COPE ± Active coping -0.002 0.038 -0.012 0.068 -0.132 
COPE ± Planning 0.048 -0.021 0.024 0.114 -0.063 
COPE ± Positive reframing -0.042 -0.068 -0.103 0.012 -0.087 
COPE ± Acceptance -0.17 -0.073 -0.1 -0.027 -0.127 
COPE ± Humor -0.069 -0.082 -0.099 -0.018 -0.088 
COPE ± Religion -0.083 0.008 -0.061 0.1 -0.015 
COPE ± Using emotional support 0.022 0.003 -0.193 -0.094 -0.08 
COPE ± Using instrumental support -0.007 0.14 -0.099 -0.074 -0.088 
COPE ± Self-distraction 0.182 .293** 0.079 .242* .264** 
COPE ± Denial 0.054 0.131 0.042 0.076 0.083 
COPE ± Venting 0.138 0.075 0.112 0.097 0.096 
COPE ± Substance use .197* .252* .318** .283** .285** 
COPE ± Behavioral disengagement 0.091 0.194 0.059 0.063 0.169 
COPE ± Self-blame -0.04 0.184 0.171 0.192 0.018 
LHIB-Q20 0.185 .209* 0.145 0.15 .204* 
HADS ± Anxiety 0.141 .246* 0.113 0.176 .216* 
HADS ± Depression 0.063 .234* 0.119 .241* 0.119 
DASS ± Stress 0.057 .215* .273** .293** .233* 
IPQ-R ± Identity 0.173 .375** 0.143 0.134 .232* 
IPQ-R ± Timeline (acute/chronic) -0.003 0.051 -0.036 0.035 -0.071 
IPQ-R ± Timeline (cyclical) 0.124 .228* 0.186 0.148 .242* 
IPQ-R ± Personal control 0.042 0.022 0.139 0.09 -0.1 
IPQ-R ± Treatment control -0.142 -0.148 0.014 -0.04 -0.161 
IPQ-R ± Coherence -0.098 0.046 -0.073 -0.089 -0.173 
IPQ-R ± Consequences 0.133 .271** 0.027 0.136 0.061 
IPQ-R ± Emotional representations 0.1 .358*** 0.146 .198* 0.139 
IPQ-R ± Psychosocial attributions 0.061 0.174 0.098 0.112 .272** 
IPQ-R ± Health attributions 0.047 0.048 0.127 0.127 0.087 
IPQ-R ± Behavioral attributions 0.135 0.074 0.076 0.052 0.175 
IPQ-R ± Environmental attributions -0.021 0.111 0.196 0.116 0.128 
IPQ-R ± Chance attributions 0 .222* 0.065 0.073 .273** 
Note. COPE = Abbreviated coping orientations to problems experienced scale. LHIB-Q20 = Life history of 
impulsive behavior questionnaire. HADS = Hospital anxiety and depression scale. DASS = Depression, anxiety 
and stress scale. IPQ-R = Illness perceptions questionnaire revised. Gamb. = Gambling. HBY-P = Hobbyism-
punding. *p < .05; **p < .01; ***p < .001 
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Table 5 
Summary of multiple regression analyses predicting Impulse Control Disorders (N =  100) 
Predictors 
Compulsive eating Hobbyism-punding 
B     SE (B) ȕ B SE (B) ȕ 
BLOCK 1       
Gender    .526 .204 .252* 
COPE ± Substance use .160 .055 .284**    
R2 .081**   .064*   
BLOCK 2       
Gender    .460 .193 .221* 
COPE ± Self-distraction    .126 .057 .205* 
COPE ± Substance use .124  .056 .219* .277 .095 .270** 
DASS - Stress .019  .008 .237*    
R2 .132*   .186**   
BLOCK 3       
Gender    .449 .192 .215* 
COPE ± Self-distraction    .093 .060 .151 
COPE ± Substance use    .236 .097 .230* 
IPQ-R ± Cause (Psychological)    .011 .017 .066 
IPQ-R ± Cause (Chance)    .069 .034 .191* 
R2    .228**   
FINAL MODEL       
Gender    .460 .193 .221* 
COPE ± Self-distraction    .126 .057 .205* 
COPE ± Substance use .124  .056 .219* .277 .095 .270** 
DASS ± Stress .019  .008 .237*    
IPQ-R ± Identity       
R2 .132*   .186**   
Predictors 
Sexual compulsions Compulsive buying 
B SE (B) ȕ B SE (B) ȕ 
BLOCK 1       
Gender .573 .167 .329**    
SE -.009 .005 -.181    
LEDD < .001 < .001 .128    
COPE - Substance use    .031 .009 .321** 
R2 .215**   .103**   
BLOCK 2       
Gender .550 .161 .315**    
SE -.008 .005 -.165    
LEDD < .001 < .001 .120    
COPE ± Self-distraction .132 .045 .257    
COPE - Substance use    .026 .009 .270** 
DASS - Stress    .003 .001 .186 
R2 .280**   .135   
BLOCK 3       
Gender .532 .153 .305**    
SE -.005 .004 -.099    
LEDD < .001 < .001 .107    
COPE ± Self-distraction .088 .047 .171    
IPQ-R - Identity .033 .012 .258**    
IPQ-R - Emotional representations .058 .017 .315**    
IPQ-R - Consequences -.035 .021 -.183    
R2 .392**      
FINAL MODEL       
Gender .532 .153 .305**    
SE -.005 .004 -.099    
LEDD < .001 < .001 .107    
40 
 
COPE ± Self-distraction .088 .047 .171    
COPE ± Substance use    .031 .009 .321** 
IPQ-R ± Identity .033 .012 .258**    
IPQ-R ± Emotional representations .058 .017 .315**    
IPQ-R ± Consequences -.035 .021 -.183    
R2 .392**   .103**   
       Note. LEDD = Levodopa equivalent daily dose. COPE = Abbreviated coping orientations to problems 
experienced scale. HADS = Hospital anxiety and depression scale. DASS = Depression, anxiety and stress 
scale. IPQ-R = Illness perceptions questionnaire revised. QUIP-RS = Questionnaire for impulsive-compulsive 
GLVRUGHUVLQ3DUNLQVRQ¶VGLVHDVHp < .05; **p < .01 
 
 
